

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

**華康生物醫學控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 8622)**

### **VOLUNTARY ANNOUNCEMENT EXTENSION OF VALIDITY PERIOD OF MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE FORMATION OF A JOINT VENTURE**

This announcement is made by Huakang Biomedical Holdings Company Limited (the “**Company**” together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping Shareholders and potential investors informed of the latest development of the Group.

Reference is made to the announcements of the Company dated 25 October 2019 and 24 April 2020 (the “**Announcements**”) in relation to the possible formation of a joint venture company in Hong Kong for, among other things, (i) research, development and registration of technology, devices and products in relation to the assisted reproductive treatment in the PRC; and (ii) sale and export of such devices and products in the PRC, countries in Asia Pacific region and other territories as may be agreed by the Parties (the “**Possible JVC Formation**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

#### **NEW VALIDITY PERIOD**

Pursuant to the terms of the MOU, the MOU lapsed on 25 October 2020. Notwithstanding the said lapse of the MOU, the Parties agree that they shall continue to negotiate the Possible JVC Formation upon the same terms of the MOU. In this connection, Huakang HK and the JV Partner require additional time to negotiate and finalize the terms in relation to, among others, the Possible JVC Formation.

The Parties have entered into a supplemental MOU (the “**Supplemental MOU**”) on 25 November 2020 (after trading hours) that (i) they shall continue to negotiate the Possible JVC Confirmation upon the same terms of the MOU, notwithstanding its previous Validity Period being lapsed on 25 October 2020; and (ii) the Validity Period under the MOU is amended to provide for a new Validity Period, being a period of six months from the date of the Supplemental MOU (i.e. 25 November 2020) (or such longer period as the Parties may otherwise agree in writing) (the “**New Validity Period**”).

Save as otherwise amended, supplemented or varied in the Supplemental MOU, all other provisions of the MOU are adopted and reconfirmed by the Parties and such terms remain unchanged and in full force and effect in accordance with their terms under the said New Validity Period.

**The Board wishes to emphasize that as at the date of this announcement, the terms and conditions of the Possible JVC Formation are still being negotiated and no legally binding agreement in relation to the Possible JVC Formation has been entered into by Huakang HK and the JV Partner (save as to the Validity Period, confidentiality, governing law and jurisdiction). Since the transactions contemplated under the MOU may or may not materialize, Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
Chairman and Executive Director

Hong Kong, 25 November 2020

*As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Yeung David Wai Chow, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*